|

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

RECRUITINGSponsored by National Cancer Institute, Naples
Actively Recruiting
SponsorNational Cancer Institute, Naples
Started2023-07-06
Est. completion2025-07
Eligibility
Age50 Years – 80 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06893861

Summary

The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.

Eligibility

Age: 50 Years – 80 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Female sex
2. Age between 50 and 80 years
3. Willingness to participate in the study and signing of the informed consent
4. Clinical condition of post-menopause

Exclusion Criteria:

1. Previous hysterectomy
2. Hormone replacement therapy
3. Immunosuppressive therapy

Conditions2

CancerEndometrial Carcinoma (EC)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.